Also, CTI was ordered to immediately pay an additional $776,454 to Spectrum by wire transfer.
Raj Shrotriya, MD, Chairman, CEO and President of Spectrum Pharmaceuticals, said: “we are very pleased with the outcome of the arbitration process, and remain very excited about the commercial potential of ZEVALIN. We continue to view the year ahead as a transformative period for Spectrum Pharmaceuticals, and we are committed to executing on our strategy and building sustainable shareholder value.”